Delays at the Food and Drug Administration have left Dornier withouta production line shock-wave lithotripter approved for sale inthe U.S. Dornier Medizintechnik of Munich has discontinued productionof its HM-4 lithotripter, while the FDA has not yet
Delays at the Food and Drug Administration have left Dornier withouta production line shock-wave lithotripter approved for sale inthe U.S. Dornier Medizintechnik of Munich has discontinued productionof its HM-4 lithotripter, while the FDA has not yet approved itssuccessor, the MFL 5000.
"The problem with being a worldwide manufacturer is youcannot run your production line solely for the U.S.," saidRobert Minton, vice president of marketing for Dornier MedicalSystems of Marietta, GA. "You have to take into considerationthe product needs of all markets."
"Adequate numbers" of HM-4s to meet forecasted needsin the U.S. have been manufactured, Minton said.
While there are HM-4s in warehouses, many, if not all, of thesesystems have been contracted for. "It is important to usthat the FDA look favorably on our new product," said RichardCline, vice president of service.
Dornier is struggling to maintain dominance of a U.S. marketit created in December 1984. Total sales of extracorporeal shock-wavelithotripsy (ESWL) units reached about 71 units in 1987 and thenplummeted, according to Market Intelligence Research of MountainView, CA. Industry sources agree that total sales in 1990 wereless than 30 units. The sluggish market is expected to continuethis year.
Siemens is challenging Dornier for leadership in this shrunkenmarket and may be succeeding.
Seventy-five percent of U.S. units installed in 1989 were SiemensLithostars, according to Laura Lee Murphy, Siemens sales managerfor lithotripsy and urology systems. Siemens' final 1990 figuresare not available.
Dornier will not comment on market share for the past two years.It has about 80% of the installed base and hopes to retain theleadership role in orders and installations, according to Minton.
Dornier officials are working with the FDA to answer specificquestions regarding its submission for the MFL 5000. The companyexpects to be back in the game soon with a production line lithotripter.
"The results of our IDE (investigational device exemption)trials were actually better than for our HM-3s (the first ESWLmachines introduced to the U.S.)," Minton said. "Basedon that track record, we're confident that the machine will gothrough approval fairly easily."
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.